Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review.

BACKGROUND Interstitial lung disease (ILD) is the leading cause of morbidity and mortality in patients with systemic sclerosis (SSc); however, prognostication of SSc-associated ILD (SSc-ILD) remains challenging. We conducted a systematic review to identify variables that predict mortality and ILD progression in SSc-ILD. METHODS Three databases were searched to identify all studies relating to predictors of mortality or ILD progression in SSc-ILD. Studies were eligible if they were published in English and included ≥ 10 adults with SSc-ILD. Two authors independently reviewed and extracted data from acceptable studies. RESULTS The initial search identified 3,145 unique citations. Twenty-seven studies, including six abstracts, met the inclusion criteria. A total of 1,616 patients with SSc-ILD were included. Patient-specific, ILD-specific, and SSc-specific variables predicted mortality and progression; however, most predictors were identified in only one study. Most studies did not fully account for potential confounders, and none of the studies included a validation cohort. Older age, lower FVC, and lower diffusing capacity of carbon monoxide predicted mortality in more than one study. Male sex, extent of disease on high-resolution CT (HRCT) scan, presence of honeycombing, elevated KL-6 values, and increased alveolar epithelial permeability were identified as predictors of both mortality and ILD progression on unadjusted analysis. The extent of disease on HRCT scan was the only variable that independently predicted both mortality and ILD progression. CONCLUSIONS Mortality and ILD progression were predicted by several patient-specific, ILD-specific, and SSc-specific factors. Additional prospective studies are required to validate these preliminary findings and to identify combinations of variables that accurately predict the prognosis of SSc-ILD.

[1]  G. La Torre,et al.  Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease , 2012, The clinical respiratory journal.

[2]  T. Medsger,et al.  Severe restrictive lung disease in systemic sclerosis. , 1994, Arthritis and rheumatism.

[3]  D. Hansell,et al.  Increased epithelial permeability in pulmonary fibrosis in relation to disease progression , 2010, European Respiratory Journal.

[4]  J. Pope,et al.  Determinants of morbidity and mortality of systemic sclerosis in Canada. , 2010, Seminars in arthritis and rheumatism.

[5]  R. D. du Bois,et al.  Exercise peripheral oxygen saturation (Spo2) accurately reflects arterial oxygen saturation (Sao2) and predicts mortality in systemic sclerosis , 2009, Thorax.

[6]  H. Collard,et al.  Prevalence and prognosis of unclassifiable interstitial lung disease , 2012, European Respiratory Journal.

[7]  R. Domsic,et al.  Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. , 2009, Arthritis and rheumatism.

[8]  T. Medsger,et al.  Changes in causes of death in systemic sclerosis, 1972–2002 , 2007, Annals of the rheumatic diseases.

[9]  C. Fanali,et al.  β-thymosins and interstitial lung disease: study of a scleroderma cohort with a one-year follow-up , 2011, Respiratory research.

[10]  D. Lynch,et al.  Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. , 2008, Chest.

[11]  L. Rubin Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.

[12]  P. Grenier,et al.  Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. , 2006, Arthritis and rheumatism.

[13]  A. Nicholson,et al.  Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. , 2002, American journal of respiratory and critical care medicine.

[14]  D. Hansell,et al.  Interstitial lung disease in systemic sclerosis: a simple staging system. , 2008, American journal of respiratory and critical care medicine.

[15]  A. Nicholson,et al.  The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. , 2002, American journal of respiratory and critical care medicine.

[16]  M. Remy-Jardin,et al.  High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. , 2006, The Journal of rheumatology.

[17]  Joyce S Lee,et al.  A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis , 2012, Annals of Internal Medicine.

[18]  Musellim Benan,et al.  The natural course of progressive systemic sclerosis patients with interstitial lung involvement , 2007, Clinical Rheumatology.

[19]  N. Prandini,et al.  Bronchoalveolar lavage in systemic sclerosis with lung involvement: role and correlations with functional, radiological and scintigraphic parameters , 2011, Rheumatology International.

[20]  B. White Interstitial lung disease in scleroderma. , 2003, Rheumatic diseases clinics of North America.

[21]  D. Hansell,et al.  Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. , 2007, Arthritis and rheumatism.

[22]  A. Lopes,et al.  Systemic sclerosis-associated interstitial pneumonia: evaluation of pulmonary function over a five-year period. , 2011, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.

[23]  K. Lee,et al.  Interstitial Pneumonia in Progressive Systemic Sclerosis: Serial High-Resolution CT Findings with Functional Correlation , 2001, Journal of computer assisted tomography.

[24]  A. Nicholson,et al.  Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. , 2003, American journal of respiratory and critical care medicine.

[25]  G. Raghu,et al.  Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. , 2010, American journal of respiratory and critical care medicine.

[26]  T. E. King,et al.  Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease , 2009, European Respiratory Journal.

[27]  B. Thiers Cyclophosphamide versus Placebo in Scleroderma Lung Disease , 2007 .

[28]  R. Scorza,et al.  T-889C IL-1α promoter polymorphism influences the response to oral cyclophosphamide in scleroderma patients with alveolitis , 2006, Clinical Rheumatology.

[29]  R. Elashoff,et al.  Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. , 2008, American journal of respiratory and critical care medicine.

[30]  M. Humbert,et al.  Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. , 2011, Chest.

[31]  Chi-Hong Tseng,et al.  Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. , 2011, Arthritis and rheumatism.

[32]  Jonathan G. Goldin,et al.  Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. , 2011, Arthritis and rheumatism.